Lubna Al-Sharif

Ms. Lubna Al-Sharif

Physiology, Pharmacology and Toxicology, Universiti Sains Islam Malaysia, Kampung Baharu Nilai, Malaysia
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2025 in Hepatology
Verified
Journal Article
Open access
MSMatheus Souza
Matheus Souza
Lubna Al-SharifLubna Al-Sharif
Lubna Al-Sharif
VAVanio L.J. Antunes
Vanio L.J. Antunes
DHDaniel Huang
Daniel Huang
RLRohit Loomba
Rohit Loomba
Background and Aims: Metabolic dysfunction-associated steatohepatitis (MASH) is a leading cause of liver disease. With the advent of multiple therapeutic targets in late-phase clinical drug development for MASH, there is a knowledge gap to better understand the comparative efficacy of various pharmacological agents. We conducted an updated network meta-analysis to evaluate the relative rank-order of the different pharmacological agents for both fibrosis regression and MASH resolution. Methods: We searched PubMed and Embase databases from 2020 to December 1, 2024, for published randomized-controlled trials (RCTs) comparing pharmacological interventions in patients with biopsy-proven MASH. The co-primary endpoints were fibrosis improvement ≥1 stage without MASH worsening and MASH resolution without worsening fibrosis. We conducted surface under the cumulative ranking (SUCRA) curve analysis. Results: A total of 29 RCTs (n=9324) were included. Pegozafermin, cilofexor + firsocostat, denifanstat, survodutide, obeticholic acid, tirzepatide, resmetirom, and semaglutide were significantly better than placebo in achieving fibrosis regression without worsening MASH. Pegozafermin (SUCRA: 79.92), cilofexor + firsocostat (SUCRA: 71.38), and cilofexor + selonsertib (SUCRA: 69.11) were ranked the most effective interventions. Pegozafermin, survodutide, tirzepatide, efruxifermin, liraglutide, vitamin E + pioglitazone, resmetirom, semaglutide, pioglitazone, denifanstat, semaglutide and lanifibranor were significantly better than placebo in achieving MASH resolution without worsening fibrosis. Pegozafermin (SUCRA: 91.75), survodutide (SUCRA: 90.87), and tirzepatide (SUCRA: 84.70) were ranked the most effective interventions for achieving MASH resolution without worsening fibrosis. Conclusion: This study provides updated rank-order efficacy of MASH pharmacological therapies for fibrosis regression and MASH resolution. These data are helpful to inform practice and clinical trial design. Export


11 December 2024 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
MSMatheus Souza
Matheus Souza
Lubna Al-SharifLubna Al-Sharif
Lubna Al-Sharif
SKSamira Mohamad Khalil
Samira Mohamad Khalil
CVCristiane Alves Villela-Nogueira
Cristiane Alves Villela-Nogueira
AMAlessandro Mantovani
Alessandro Mantovani

26 December 2024 in Journal of Clinical and Experimental Hepatology
Verified
Journal Article
Closed access
MSMatheus Souza
Matheus Souza
Lubna Al-SharifLubna Al-Sharif
Lubna Al-Sharif
IDIvanna Diaz
Ivanna Diaz
AMAlessandro Mantovani
Alessandro Mantovani
CVCristiane Alves Villela-Nogueira
Cristiane Alves Villela-Nogueira

15 August 2023 in Cureus
Verified
Journal Article
Open access
PDF file
ARAlex Roman
Alex Roman
Lubna Al-SharifLubna Al-Sharif
Lubna Al-Sharif
MGMohamed AL Gharyani
Mohamed AL Gharyani
The objective of this study is to explore the use of ChatGPT (Chat-Generative Pre-Trained Transformer) in neurosurgery and its potential impact on the field. The authors aim to discuss, through a systematic review of current literature, how this rising new artificial intelligence (AI) technology may prove to be a useful tool in the future, weighing its potential benefits and limitations. The authors conducted a comprehensive and systematic literature review of the use of ChatGPT and its applications in healthcare and different neurosurgery topics. Through a systematic review of the literature, with a search strategy using the databases such as PubMed, Google Scholar, and Embase, we analyzed the advantages and limitations of using ChatGPT in neurosurgery and evaluated its potential impact. ChatGPT has demonstrated promising results in various applications, such as natural language processing, language translation, and text summarization. In neurosurgery, ChatGPT can assist in different areas such as surgical planning, image recognition, medical diagnosis, patient care, and scientific production. A total of 128 articles were retrieved from databases, where the final 22 articles were included for thorough analysis. The studies reviewed demonstrate the potential of AI and deep learning (DL), through language models such as ChatGPT, to improve the accuracy and efficiency of neurosurgical procedures, as well as diagnosis, treatment, and patient outcomes across various medical specialties, including neurosurgery. There are, however, limitations to its use, including the need for large datasets and the potential for errors in the output, which most authors concur will need human verification for the final application. Our search demonstrated the potential that ChatGPT holds for the present and future, in accordance with the studies’ authors’ findings herein analyzed and expert opinions. Further research and development are required to fully understand its capabilities and limitations. AI technology can serve as a useful tool to augment human intelligence; however, it is essential to use it in a responsible and ethical manner.

26 July 2024 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
KAKarim Ataya
Karim Ataya
NPNeha Patel
Neha Patel
AAAlmoutuz Aljaafreh
Almoutuz Aljaafreh
SMSamah Sofyan Melebari
Samah Sofyan Melebari
WYWah Yang
Wah Yang
OCon behalf of Global Obesity Collaborative
on behalf of Global Obesity Collaborative